Thank Jeff. you,
our moving support are data on forward Phase pelabresib. applications with study, marketing for package also to we we are completing As non-clinical the III working ultimately
our disclosed last one potential of have we had results, call, We assess while we preclinical completed the shared provided genotoxic our instance, development activities. and On all these genotoxicity to continuing previously two clinical the the pelabresib. FDA on updating For that additional did studies results informed patient's not. earnings studies the our form, positive now with line consent studies the of while
that FDA, unusual to have is findings. it on and types our follow-up reconcile proposed results In preclinical these previous setting, development the conduct have initial the now we not discussions that myelofibrosis. studies. with in path Based impact genotoxic currently observations we believe findings also to The pelabresib oncology these to will has studies of pelabresib show these additional We two do therapies conducted the of the potential. not for
in Beyond completing submission. needed XX. that, progress we are making studies other NDA to slide non-clinical turn Please good to support
of plan to an our MANIFEST II update additional are As recent data update intriguing end, opportunity. translational durability additional we responses data our that Jeff followed help depth patients for in our and myelofibrosis, with to mentioned, translational and clinical on provide where our expansive we clinical engaged of In will to by we midyear, continue from data the from encouraging our could ASH to mechanisms pelabresib. Phase collect provide update options are response to update exploring study. attempt therapeutic and We the expand a by novel year's
internally candidate, led is next product excited an slide discovered One which of commonly from development like CPI-XXX as on us completing for demethylase that selective referred our removes I attention IND-enabling would about and CPI-XXX, and to these the expression. LSDX are of the your has XX. efforts as we turn regulation now thereby focused modifications to enzyme. declare developing studies. to CPI-XXX, a in We're LSDX to functions inhibitor chromatin potent gene epigenetic an on of candidate eraser,
as including cells, proper cell for hematopoietic myelofibrosis, megakaryocytic blood overproduction of aberrant cell the Importantly, blood in interfere a features may key megakaryocytes, is population functions In CPI-XXX the the ability of cytokines. and required erythroid stem inflammatory differentiation prevent malignant and myelofibrosis, to well may of a we maintenance of replenish cells with CPI-XXX of the that cells. of of various cell differentiation believe the pool disease driver for the context development is stem of that LSDX as Moreover, lineages. of
is LSDX volume the EZHX believe profile the hematologic from in As turn shown we second-generation our inhibitors our our benefit to other strategy expand in on differentiated CPI-XXX tumors. I myelofibrosis. spleen right-hand to for efforts CPI-XXX MPN range CPI-XXXX, side, on has in inhibitor different and update to mouse opportunities ruxolitinib. encouraging aimed model a and a development in has would XX. solid slide also malignancies shown of post reduction outcompeted you which survival Please developing clinical that CPI-XXX like in
that improve including recall a ways, and will of number its CPI-XXXX first-generation on increased EZHX inducing designed we by long You in to time residence levels exposure metabolism. inhibitors potency, maintaining not own
profile on EZHX Please with therapeutic discussed the full CPI-XXXX As may of call, potential that last our type of to turn slide biology. earnings XX. extract
advanced We for Phase I/II CPI-XXXX and study are hematologic currently with with conducting tumors. solid patients a
in have of have evidence seen increase metabolism. and dose-dependent compound with a We multiple cohorts dose no of exposure induction completed
seen EZHX patients I with by also some The on EZHX consistent in of high compound the with a CPI-XXXX treatment increases of interested pharmacodynamic the It see XX subsets Please assessment of EZHX encouraging whereby, The of to and expression dependence here We loss-of-function cycle XX. in expression respectively. context of regulatory have data on mutations a to initial increases indications. CPI-XXXX. blue compared or illustration as would that colors target the are performance expression gene of of respect at expression a such to we measured observed the the you such as ARIDXA treatment. or first the red first the and increasing with for from like dose-dependent by CPI-XXXX cohorts, of markers. development in blood gene CPI-XXXX. heat map as create on we left of pharmacodynamic four BES-X left of chromatin in target the genomic potential. aspirations expression day gene in lymphoma profiling multiple for itself in tumor with dose as Shown indicated proteins shows to once-daily is the aberrations with expression, observed that certain where reminder shows We mutations of low solid turn our of several doses as engagement genes with best-in-class leave modulation that gene believe of of whereby, markers the magnitude molecular is baseline function functional in a gain slide context are
androgen determining in as continue with exploration on CPI-XXXX receptor prostate to based After our cancer targeted interested EZHX of or agents functional portion of for indication into move of inhibitors the also in models. be We safety the to trial in effects we X turn an the cooperation rapidly CPI-XXXX's prostate cancer cancer call AR the establishing well-defined RPXD, I plan And the Phase this will to over and to Emma. test therapeutic now context.
